Drug Patents owned by Sucampo Pharma Llc
1. List of Amitiza drug patents
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7064148 | SUCAMPO PHARMA LLC | Chloride channel opener |
Aug, 2022
(9 months ago) | |
| US8097653 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(6 months ago) | |
| US8389542 | SUCAMPO PHARMA LLC | Dosage unit comprising a prostaglandin analog for treating constipation |
Nov, 2022
(6 months ago) | |
| US6982283 | SUCAMPO PHARMA LLC | Method for treating drug-induced constipation |
Dec, 2022
(5 months ago) | |
| US7795312 | SUCAMPO PHARMA LLC | Method for treating abdominal discomfort |
Sep, 2024
(1 year, 3 months from now) | |
| US8748481 | SUCAMPO PHARMA LLC | Method for treating gastrointestinal disorder |
Sep, 2025
(2 years from now) | |
| US8779187 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(3 years from now) | |
| US8338639 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Jan, 2027
(3 years from now) | |
| US8026393 | SUCAMPO PHARMA LLC | Soft-gelatin capsule formulation |
Oct, 2027
(4 years from now) | |
Drugs and Companies using LUBIPROSTONE ingredient
Market Authorisation Date: 31 January, 2006
Treatment: Method for treating constipation in a patient with opioid-induced constipation by opening cic channels; Method of treating constipation in a patient with irritable bowel syndrome by opening chloride c...
Dosage: CAPSULE;ORAL
AMITIZA family patents
25
United States
18
Japan
11
Argentina
8
Korea, Republic of
8
European Union
7
China
6
Canada
6
Spain
6
Brazil
5
Australia
5
New Zealand
5
Mexico
5
Taiwan
4
Denmark
4
Portugal
3
Norway
2
Israel
2
Austria
2
Russia
1
Luxembourg
1
Cyprus
1
Hong Kong
1
Germany
1
South Africa
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic